Following the approval of exendin-4 (a GLP-1 receptor agonist) for T2DM, a small retrospective analysis of five patients with SBS was conducted: exendin-4 reduced antral contractions both on an empty stomach and after meals, slowed gastric emptying and prolonged chyme contact with the absorbing mucosa, resulting in improved evacuation frequency and reduced need for total parenteral nutrition [103]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.